Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ono Pharmaceutical Co., Ltd. | INDUSTRY |
This study will be focused on HNC patients who have been diagnosed with HNC between 01-Jan-2013 and 30-Sep-2016.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HNC patients | HNC patients who have been diagnosed with HNC between 01-Jan-2013 and 30-Sep-2016. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Non-Interventional | Other | Non-Interventional |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients receiving radiotherapy as anti-cancer treatment | Approximately 45 months | |
| Proportion of patients receiving surgery as anti-cancer treatment | Approximately 45 months | |
| Proportion of patients receiving chemotherapy as anti-cancer treatment | Approximately 45 months | |
| Proportion of patients receiving targeted therapy as anti-cancer treatment | Approximately 45 months | |
| Proportion of patients receiving supportive care as anti-cancer treatment | Approximately 45 months | |
| Distribution of Treatment History in Head and Neck Cancer (HNC) patients | Approximately 45 months |
| Measure | Description | Time Frame |
|---|---|---|
| Distribution of overall survival (OS) by age | Approximately 45 months | |
| Distribution of overall survival (OS) by gender | Approximately 45 months | |
| Distribution of overall survival (OS) by stage |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients in the Medical Data Vision (MDV) database with a HNC diagnosis will be used to identify eligible subjects by applying the patient inclusion and exclusion criteria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | Tokyo | Shibuya-ku | 150-0002 | Japan |
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
| Investigator Inquiry Form | View source |
| FDA Safety Alerts and Recalls |
Not provided
Not provided
| ID | Term |
|---|---|
| D006258 | Head and Neck Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Approximately 45 months |
| Distribution of overall survival (OS) by tumor site | Approximately 45 months |
| Distribution of overall survival (OS) by treatment regimen | Approximately 45 months |
| Number of treatment-limiting adverse events (AEs) | Incidence of important treatment-limiting adverse events (AEs) associated with systemic therapies | Approximately 45 months |
| Number of withdrawals due to AEs | Approximately 45 months |
| Proportion of diagnosis of another malignancy on or before the initial diagnosis of HNC | At Baseline |